This proposal is submitted in response to RFA-HL-06-108 for the Limited Competition for the Continuation of the Transfusion Medicine /Hemostasis Clinical Research Network, a nationally developed network of interactive clinical research groups. With this application, the Transfusion Medicine Program at Emory University seeks to continue funding as a Core Clinical Center within the Network. As a Core Clinical Center we have and will continue to contribute scientific concepts and to protocol development;participate in the overall administration of the clinical trials through the national Steering Committee and Data Coordinating Center;adhere to national and institutional guidelines and regulatory requirements related to research involving human subjects;accrue eligible patients to trials selected to be conducted by the Network;and disseminate findings through timely publications and presentations of data. As a Core Clinical Center of the Clinical Research Network we will continue to pursue the following Specific Aims, to: 1) maintain, and further develop, as needed, a structure to support the development, implementation and conduct of clinical trials in the areas of transfusion medicine and hemostasis. This will be done in collaboration with the New England Research Institutes as Data Coordinating Center, and program staff at NHLBI;2) utilizing a structure of working and study oversight subcommittees, complete ongoing trials and develop, refine and complete new trials proposed in this application;3) develop collaborative relationships and support training opportunities to facilitate the success of the proposed clinical trials and further the fields of transfusion medicine and hemostasis. Over the past 5 years, Emory University investigators have actively participated at Steering Committee meetings, enrolled patients on the PLADO trial, obtained IRB approval for SHIP, and continued to work on obtaining IRB approval for the RICH trial. The Emory Core Clinical Center has developed the personnel and procedures to ensure optimal participation and future productivity.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01HL072248-09
Application #
7928798
Study Section
Special Emphasis Panel (ZHL1-CSR-J (M1))
Program Officer
Mondoro, Traci
Project Start
2002-09-30
Project End
2013-08-31
Budget Start
2010-09-01
Budget End
2012-08-31
Support Year
9
Fiscal Year
2010
Total Cost
$155,723
Indirect Cost
Name
Emory University
Department
Pathology
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Uhl, Lynne; Assmann, Susan F; Hamza, Taye H et al. (2017) Laboratory predictors of bleeding and the effect of platelet and RBC transfusions on bleeding outcomes in the PLADO trial. Blood 130:1247-1258
Kaufman, Richard M; Assmann, Susan F; Triulzi, Darrell J et al. (2015) Transfusion-related adverse events in the Platelet Dose study. Transfusion 55:144-53
Leissinger, C; Josephson, C D; Granger, S et al. (2014) Rituximab for treatment of inhibitors in haemophilia A. A Phase II study. Thromb Haemost 112:445-58
Josephson, Cassandra D; Granger, Suzanne; Assmann, Susan F et al. (2012) Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia. Blood 120:748-60
Triulzi, Darrell J; Assmann, Susan F; Strauss, Ronald G et al. (2012) The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia. Blood 119:5553-62
Josephson, Cassandra D; Glynn, Simone A; Kleinman, Steve H et al. (2011) A multidisciplinary ""think tank"": the top 10 clinical trial opportunities in transfusion medicine from the National Heart, Lung, and Blood Institute-sponsored 2009 state-of-the-science symposium. Transfusion 51:828-41
Slichter, Sherrill J; Kaufman, Richard M; Assmann, Susan F et al. (2010) Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 362:600-13
Steiner, M E; Assmann, S F; Levy, J H et al. (2010) Addressing the question of the effect of RBC storage on clinical outcomes: the Red Cell Storage Duration Study (RECESS) (Section 7). Transfus Apher Sci 43:107-16
Slichter, Sherrill J (2006) Background, rationale, and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients. J Clin Apher 21:78-84